-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARM-210 in Ventricular Tachycardia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARM-210 in Ventricular Tachycardia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARM-210 in Ventricular Tachycardia Drug Details: ARM-210 is under development for...
-
Product Insights
ARM Ltd Partner Ecosystem Profile
GlobalData's new report titled "ARM Ltd Partner Ecosystem Profile " serves as a crucial resource for analyzing the partner landscape of ARM Ltd. It identifies the company's partners across various countries and regions, and tracks over 70 data fields including IT solution areas of interest, business fundamental data (such as revenue and employee bands), partner engagement signing country, focused verticals, and more.It is based on data and information gathered from a range of sources including company websites, press releases, CXO...
-
Sector Analysis
NewC-Arms Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
C-Arms Market Overview The C-Arms market size was $1.92 billion in 2023. Factors such as the increasing number of surgical procedures that require intraoperative imaging and advancements in maneuverability and imaging capabilities will drive the market growth at a CAGR of more than 3% from 2023 to 2033. C-Arms are primarily used for fluoroscopic imaging during surgical, orthopedic, critical care, traumatology, cardiology, and emergency care intraoperative procedures. Mobile C-Arms are devices with wheels attached to allow for free movement throughout...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-217 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-217 in Relapsed Multiple Myeloma Drug Details: HPN-217 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-217 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-217 in Refractory Multiple Myeloma Drug Details: HPN-217 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1821736 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1821736 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1821736 in Solid Tumor Drug Details: BI-1821736 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Faricimab in Choroidal Neovascularization
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Faricimab in Choroidal Neovascularization report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Faricimab in Choroidal Neovascularization Drug Details: Faricimab (Vabysmo, Babismo) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Faricimab in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Faricimab in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Faricimab in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: Faricimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in B-Cell Non-Hodgkin Lymphoma Drug Details: Mosunetuzumab (Lunsumio) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...